Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

You may be eligible if

• One of the following histologically confirmed diagnoses:
• * Renal cell cancer
• * Clear cell histology
• * Metastatic or unresectable disease AND meets 1 of the following criteria:
• * Recurrent disease
• * Refractory to interleukin-2 (IL-2)- or interferon-based therapy
• * Previously untreated AND not a candidate for IL-2-based therapy
• * Colorectal, head and neck, pancreatic, or non-small cell lung cancer
• * Metastatic or unresectable disease
• * Progression after prior standard treatment
• No evidence of CNS disease, including the following (part 2 only):
• * Primary brain tumor
• * Brain metastases
• Paraffin embedded tumor blocks available
• Performance status - ECOG 0-2
• Performance status - Karnofsky 60-100%
• More than 12 weeks
• Absolute neutrophil count ≥ 1,500 mm\^3
• Platelet count ≥ 100,000 mm\^3
• Bilirubin ≤ 1.5 mg/dL
• AST and ALT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastasis is present)
• PTT and INR ≤ 1.5, unless receiving full-dose warfarin (part 2 only)
• Creatinine ≤ 1.5 times ULN
• Creatinine clearance ≥ 60 mL/min
• Calcium \< 10 mg/dL (hypocalcemic agents allowed)
• No proteinuria\*
• Protein \< 1 g on 24-hour urine collection\*
• No unstable angina pectoris
• No cardiac arrhythmia
• No symptomatic congestive heart failure
• None of the following are allowed for part 2:
• * Myocardial infarction within the past 6 months
• * New York Heart Association class II-IV heart disease
• * Serious cardiac arrhythmia requiring medication
• * Peripheral vascular disease ≥ grade II
• * Recent history of cerebrovascular accident
• * Uncontrolled hypertension (blood pressure ≥ 150/85 mm Hg despite medication)
• * Other clinically significant cardiovascular disease
• No gastrointestinal (GI) tract disease resulting in an inability to take oral medication
• No GI tract disease resulting in a requirement for IV alimentation
• No active peptic ulcer disease
• No history of allergic reaction attributed to compounds of similar chemical or biologic composition to study drugs
• No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies (part 2 only)
• No ongoing or active infection
• No active infection requiring parenteral antibiotics (part 2 only)
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 2 months after study treatment
• No significant traumatic injury within the past 28 days (part 2 only)
• No history of abnormalities of the cornea (e.g., dry eye syndrome, Sjögren's syndrome, or congenital abnormality \[e.g., Fuch's dystrophy\])
• No other malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the breast or cervix
• No psychiatric illness or social situation that would preclude study compliance
• No serious or non-healing wound ulcer or bone fracture (part 2 only)
• No other uncontrolled illness
• See Disease Characteristics
• More than 4 weeks since prior immunotherapy
• No prior cetuximab
• No prior bevacizumab
• Concurrent epoetin alfa or darbepoetin alfa allowed
• More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
• More than 4 weeks since prior radiotherapy
• No prior surgical procedures affecting absorption
• Prior nephrectomy or resection of metastatic lesions allowed provided patient has fully recovered
• More than 7 days since prior core biopsy\*
• More than 28 days since prior major surgery or open biopsy\*
• No concurrent major surgery\*
• Recovered from all prior therapy
• No prior erlotinib
• Concurrent bisphosphonates allowed
• Concurrent full-dose anticoagulants allowed provided the following criteria are met (part 2 only):
• * In-range INR (usually between 2 and 3) AND on a stable dose of warfarin or low molecular weight heparin
• * No active bleeding
• * No pathological conditions that carry a high risk of bleeding (e.g., tumor involving major vessels or varices)
• No other concurrent investigational agents
• No concurrent combination antiretroviral therapy for HIV-positive patients
• No other concurrent anticancer therapy